Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results

 
• By Joseph Haas
  
Research analyst adding reagent to drug to keep tracking chemical reaction - Image
Lilly and Pfizer's latest clinical data for tanezumab did not de-risk the drug's safety
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D